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Abstract
Introduction: The aim of the study was to assess quality of life (QoL) in patients with infiltrative form of Graves’ ophthalmopathy (GO)
during the combined pulse treatment with methylprednisolone and orbital radiotherapy, and also to search for the relation between the
results of ophthalmopathy treatment and changes in QoL.
Material and methods: The study involved 29 patients aged 25–74 (the mean age: 52 ± 6 years) with infiltrative form of GO. They were
classified for ophthalmopathy treatment on the basis of the following factors: the obtained euthyreosis, progressive character of eye
changes, the level of eye changes determined on the basis of NO SPECS classification (at least class 3c), ophthalmopathy index (OI)
according to Donaldson ≥ 4. GO was diagnosed as active if CAS (clinical activity score) ≥ 4. During the treatment, the patients received
6 cycles of methylprednisolone sodium succinate in doses of 1,0 g/24 h given as one-hour-long intravenous infusions for three successive
days in a week. Between the 2nd and 4th cycle of Solu-Medrol, orbital radiotherapy with 10 MeV X-rays was performed. The control group
was made up of healthy volunteers selected with regard to sex, age, educational background and nicotine addiction so as they correspon-
ded with the study group. It involved 53 individuals aged 21–75 (the mean age: 52,4 ± 14 years). QoL was assessed by means of the MOS
SF-36 questionnaire.
Results: Patients with GO evaluated their QoL lower than healthy individuals, which referred to physical functioning, physical and
emotional role functioning, general health, vitality, social functioning, mental health and bodily pain. No correlation was found between
quality of life and such factors as age, sex, or duration time of Graves disease and ophthalmopathy. Analogically, no relation was observed
between the activity and stage of clinical development of eye changes and QoL. The use of the combined GO therapy contributed to
a considerable decrease in the development of eye changes and the disease activity. After treatment, the patients’ QoL improved which
referred to physical role functioning, bodily pain, and vitality. Other QoL parameters did not statistically significantly differ.
Conclusions: GO causes a considerable worsening of QoL. The stage of clinical development and activity of GO find no reflection in QoL.
Effectiveness of treatment for GO cannot be evaluated on the basis of changes in QoL. (Pol J Endocrinol 2009; 60 (3): 158–165)
Key words: Graves’ ophthalmopathy, Graves’ disease, quality of life, methylprednisolone, orbital radiotherapy
Streszczenie
Wstęp: Celem pracy była ocena jakości życia u chorych z naciekową postacią oftalmopatii tarczycowej (GO, Graves’ opthalmopathy)
w trakcie pulsacyjnego leczenia metylprednizolonem w połączeniu z radioterapią oczodołów oraz próba odniesienia wyników leczenia
oftalamopatii do zmian w jakości życia.
Materiał i metody: Badaniem objęto grupę 29 pacjentów w wieku 25–74 lat (śr. wieku: 52 ± 6 lat) z naciekową GO. Podstawą kwalifikacji
chorych do leczenia oftalmopatii było uzyskanie eutyreozy, postępujący charakter zmian ocznych, stopień zaawansowania zmian ocznych
oceniany w oparciu o klasyfikację NO SPECS mieszczący się przynajmniej w klasie 3c, indeks oftalmopatii według Donaldson ≥ 4 punk-
tów. Za aktywną postać GO przyjmowano wartości klinicznego wskaźnika aktywności (CAS, clinical activity score) ≥ 4. Podczas leczenia,
u chorych zastosowano 6 cykli soli sodowej metyloprednizolonu w dawce 1,0 g/dobę podczas jednogodzinnych wlewów dożylnych,
przez kolejne trzy dni w tygodniu. Między 2. a 4. cyklem Solu-Medrolu prowadzono radioterapię tkanek pozagałkowych promieniami X
o energii 10 MeV. Grupę kontrolną utworzono ze zdrowych ochotników, dobranych w stosunku do grupy badanej pod względem płci,
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wieku, posiadanego wykształcenia i uzależnienia od nikotyny. Składała się ona z 53 osób, w wieku 21–75 lat (śr. wieku: 52,4 ± 14 lat).
Badania jakości życia przeprowadzano, opierając się na kwestionariuszu MOS SF-36.
Wyniki: Pacjenci z GO gorzej oceniali jakość życia w stosunku do osób zdrowych w zakresie ogólnej sprawności, ograniczeń fizycznych
i emocjonalnych w pełnieniu funkcji, stanu zdrowia, witalności, funkcjonowania społecznego, zdrowia psychicznego oraz występowania
i nasilenia bólu. Nie wykazano korelacji pomiędzy jakością życia a wiekiem, płcią, czasem trwania choroby Gravesa-Basedowa i oftalmo-
patii. Podobnie nie stwierdzono zależności pomiędzy aktywnością i zaawansowaniem klinicznym zmian ocznych a jakością życia. Zasto-
sowanie skojarzonej terapii GO spowodowało znamienne zmniejszenie stopnia zaawansowania zmian ocznych i obniżenie aktywności
choroby. Po leczeniu pacjenci wskazali na poprawę jakości życia w zakresie ograniczeń fizycznych w odgrywaniu ról, występowania
i nasilenia bólu oraz witalności. Pozostałe parametry jakości życia nie różniły się istotnie statystycznie.
Wnioski: Oftalamopatia tarczycowa powoduje znaczne pogorszenie jakości życia. Stopień zaawansowania klinicznego i aktywność oftal-
mopatii nie wykazują związku z jakością życia. Skuteczności leczenia oftalmopatii nie można oceniać, kierując się zmianami w jakości
życia pacjentów. (Endokrynol Pol 2009; 60 (3): 158–165)
Słowa kluczowe: oftalmopatia tarczycowa, choroba Gravesa-Basedowa, jakość życia, metyloprednizolon, radioterapia oczodołów
tients afflicted with GO have problems with proper func-
tioning in the family and society. Many patients face se-
rious difficulties in continuing their work at existing posts.
The aim of this study was to assess the quality of life
in patients with the infiltrative form of Graves’ ophthal-
mopathy treated with cycles of methylprednisolone and
orbital radiotherapy, and to search for the relation be-
tween the results of ophthalmopathy treatment and
changes in quality of life.
Material and methods
The study involved 29 patients aged 25–74 (mean age:
52 ± 6 years) with progressive infiltrative ophthalmo-
pathy developed in the course of Graves-Basedow di-
sease. In 4 patients hyperthyroidism was previously tre-
ated with 131I, and 4 others underwent strumectomy.
The rest of the patients received conservative treatment
with thyreostatics. All the patients were in a state of cli-
nical euthyreosis at the beginning of GO therapy. The
duration of Graves-Basedow disease was 8–64 months,
37.4 ± 7 months on average. GO-related eye changes
lasted 1–16 months, 8 ± 3 months on average.
The patients were classified for ophthalmopathy tre-
atment on the basis of the following factors: the obta-
ined euthyreosis, progressive character of eye changes,
the level of eye changes determined on the basis of NO
SPECS classification (at least class 3c), and ophthalmo-
pathy index according to Donaldson ≥ 4, (Table I) [8].
GO was diagnosed as active if CAS (clinical activity sco-
re) ≥ 4 [9]. Maximum opthalmopathy index (OI) and CAS
values were 15 and 7, respectively. Opthalmopathy in-
dex and CAS were calculated for each eye separately.
Exclusion criteria for deciding that a patient was not
allowed to participate in the therapy included: coexi-
stence of an autoimmunological disease, relapsing form
of Graves’ ophthalmopathy, administration of oral ste-
roids before hospital admission, treatment by means of
orbital irradiation only or cyclical administration of
methylprednisolone only, cessation of treatment becau-
se of complications, cessation of oral treatment with
Introduction
Graves’ ophthalmopathy (GO) is the most common
non-thyroid clinical manifestation of Graves’ disease [1].
It develops in 25–50% of patients afflicted with this con-
dition. In most cases, eye symptoms result from hyper-
thyroidism and increased activation of the sympathetic
nervous system. They manifest as small oedemas of the
upper and lower eyelids, widening of the palpebral fis-
sure, slight exophthalmos, and excessive lacrimal secre-
tion. The clinical course of the disease is mild. During
treatment for hyperthyroidism, the described changes
usually naturally regress [2]. In some patients, such
changes may become established, but they do not pro-
duce any trouble and do not cause visual impairment.
The infiltrative form of GO is observed in 5–8% of
patients with Graves’ disease [3]. Eye changes appear
as a consequence of an inflammatory process which
has an autoimmunological character and spreads over
orbital soft tissue. This form of ophthalmopathy usual-
ly has a progressive character and, if not treated, can
even lead to the loss of sight. Pathological lesions mani-
fest as massive circumorbital oedema, considerable exo-
phthalmos, diplopia, reduced visual acuity, and dama-
ged cornea.
Infiltrative ophthalmopathy requires the combined
immunosuppressive therapy, initially with methylpred-
nisolone and orbital radiotherapy, and then continu-
ation with prednisone. At present, this is the most ef-
fective treatment for this disease.
Analysis of the regression level of particular clinical
GO symptoms is not the only essential element of the
applied treatment efficacy; it is also important to fully
restore the patient’s general fitness, which guarantees
their proper functioning in the family and society. Qu-
ality of life is measured by means of questionnaires.
Both Graves’ disease and Graves’ ophthalmopathy
contribute to a considerable worsening of quality of life.
Unfavourable changes are related to the sphere of physi-
cal functioning, physical and emotional role functioning,
vitality, social functioning, and mental health [4–7]. Pa-
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prednisone, or a patient’s refusal to be examined after
completing the full therapy.
Ophthalmological examinations included: visual
acuity determination checking for near- and farsigh-
tedness, eyeball protrusion measured with a Hertel
exophthalmometer at the same eyeball distance each
time, measurement of palpebral fissure width, slit lamp
examination of the front part of the eye considering
corneal damages, eyeball mobility and diplopia exa-
mination, ophthalmoscopy, and measurement of in-
traocular pressure.
Ophthalmological examinations were performed
twice, i.e. before and after the pulse treatment with
methylprednisolone.
The treatment scheme was based on therapy with
glucocorticoids combined with orbital irradiation. The
patients received 6 cycles of methylprednisolone sodium
succinate (Solu-Medrol TM Pharmacia & Upjohn). Each
cycle was composed of three one-hour-long intraveno-
us infusions of methylprednisolone in doses of 1.0 g/24 h,
administered for three successive days in a week.
The control group consisted of healthy volunteers
selected with regard to sex, age, educational backgro-
und, and nicotine addiction, so that they corresponded
with the study group. This involved 53 individuals aged
21–75 (mean age: 52.4 ± 14 years).
On the day of ophthalmological examination, each
patient’s quality of life was assessed by means of the MOS
SF-36 (Medical Outcomes Study Short-Form-36), which
included analysis of physical functioning, physical and
emotional role functioning, bodily pain, general health,
vitality, social functioning, and mental health [10]. In the
control group, quality of life was assessed once.
Statistical analysis
Normality of distribution of the continuous variables
was analysed using Shapiro-Wilk test. Before compari-
son of the mean values, variance homogeneity was ana-
lysed (F-Snedecor test). Statistical significance of para-
meters in the particular groups was assessed using the
non-parametric Mann-Whitney U test. In order to as-
sess the correlation between two measurable continu-
ous characteristics, Pearson’s correlation coefficient was
calculated when the distribution of both characteristics
corresponded with normal distribution, and Spearman’s
rank correlation coefficient was used when the distri-
bution of at least one of the characteristics was statisti-
cally significantly different than normal. Statistical si-
gnificance was defined as p < 0.05.
Results
After the 6-week combined therapy with methylpred-
nisolone and orbital radiotherapy, a statistically signifi-
cant decrease in the development of eye changes was
obtained, which was expressed as considerably lower
OI values in both eyes. In addition, the applied treat-
ment contributed to a considerable decrease in the di-
sease activity (Table II).
Positive correlations between OI and CAS values
were proven both before treatment and after 6 cycles
of methylprednisolone combined with orbital radiothe-
rapy (Fig. 1, Fig. 2).
In the group of GO patients, no correlation was ob-
served between quality of life and such factors as age,
sex, or duration time of Graves’ disease and Graves’
Table I. Categories of eye changes in Graves-Basedow disease according to Donaldson
Tabela I. Kategorie zmian ocznych w chorobie Gravesa-Basedowa według Donaldson
Orbital Exophthalmos Eye muscles Cornea Visual Result
soft tissue in mm above acuity
the upper
normal limit
Slight conjunctival 3–4 Occasional Minimal 0.8–0.5 1
congestion, eyelid diplopia at stippling
oedema, mild extreme position
symptoms of eyeballs
Moderate 5–7 Frequent diplopia, Considerable 0.45–0.2 2
conjunctival moderate stippling
congestion, eyelid limitation of
oedema, medium eyeball mobility
symptoms
Severe conjunctival > 8 Persistent diplopia, Ulceration < 0.2 3
congestion and substantially impaired
oedema, massive eyeball mobility
eyelid oedema,
severe symptoms
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Table II. Comparison of the stage and the activity of Graves’ ophthalmopathy before and after treatment
Tabela II. Porównanie stopnia zaawansowania klinicznego i aktywności oftalmopatii tarczycowej przed i po leczeniu
Before After
treatment treatment *p < 0.05
Stage of Graves’ ophthalmopathy (OI) Right eye 5.1 ± 2.1 1.3 ± 1.4 *
Left eye 4.9 ± 2.2 1.3 ± 1.5 *
Average score of two eyes 4.9 ± 1.9 1.3 ± 1.4 *
Activity of Graves’ ophthalmopathy (CAS) Right eye 5.2 ± 2.6 1 ± 1 *
Left eye 5.1 ± 3.0 1.1 ± 1.2 *
Average score of two eyes 5.1 ± 2.5 1 ± 1 *
*Test for Spearman rank correlation coefficient
Figure 1. Correlation between the activity (CAS) and stage of
clinical development of Graves’ ophthalmopathy (OI) before
treatment
Rycina 1. Korelacja pomiędzy aktywnością (CAS) i stopniem
zaawansowania klinicznego oftalmopatii (IO) przed rozpoczęciem
leczenia
Figure 2. Correlation between the activity (CAS) and stage of
clinical development of Graves’ ophthalmopathy (OI) after
treatment
Rycina 2. Korelacja pomiędzy aktywnością (CAS) i stopniem
zaawansowania klinicznego oftalamopatii tarczycowej (IO) po
leczeniu
Table III. Quality of life assessment depending on educational background in the group of Graves’ ophthalmopathy patients
Tabela III. Ocena jakości życia w zależności od wykształcenia w grupie pacjentów z oftalmopatią tarczycową
Parameter Elementary school level High school level University level *p
Physical functioning 65± 47.6 57.2± 30.2 82.5± 9.5 0.75
Role functioning — physical 8.3± 14.4 13.8± 33.3 12.5± 25 0.96
Bodily pain 38.3± 37.0 55.3± 25.2 46.7± 18.7 0.89
General heath 58.2± 10.5 47.1± 20.5 54.7± 21.2 0.66
Vitality 45± 31.2 43.8± 12.9 38.7± 10.3 0.43
Social functioning 37.5± 21.6 44.4± 31.3 46.8± 11.9 0.69
Role functioning — emotional 0± 0 44.4± 52.7 75± 50 <0.05
Mental health 56± 4 58.2± 25.3 61± 7,5 0.59
*Test for Spearman rank correlation coefficient
Education
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ophthalmopathy. The higher level of education of oph-
thalmopathy patients was reflected in better emotional
role functioning compared to individuals with only pri-
mary or high school level education (Table III).
However, no correlation was found between the sta-
ge of Graves’ ophthalmopathy or activity and quality
of life in these patients.
In the control group, the women assessed their qu-
ality of life higher than men when referring to vitality;
they also complained less about physical and emotio-
nal limitations in role functioning, and evaluated their
social functioning higher (Table IV).
The younger the surveyed were, the higher they
assessed their physical functioning, physical role
functioning, and general health (p < 0.08). There
were no significant correlations between other para-
meters of quality of life and age in the control group.
In the healthy individuals, a high level of education
was associated with better assessment of physical
functioning and considerably lower levels of bodily
pain (Table V).
Quality of life patients with infiltrative ophthalmo-
pathy before the therapy was significantly different than
in the healthy individuals, which referred to all asses-
sed parameters, namely physical functioning, physical
role functioning, bodily pain, general health, vitality,
social functioning, emotional role functioning, and
mental health (Fig. 3).
The use of the combined therapy for Graves’ oph-
thalmopathy significantly reduced the intensity of eye
changes and the activity of the disease, and at the same
time considerably improved the quality of life related
to physical role functioning, bodily pain, and vitality
(Fig. 4). In accordance with patients’ opinions, other pa-
rameters did not change to any statistical significance.
The older the examined patients were, the more the-
ir mental health improved after the applied treatment
(Rs = 0.47, p < 0.02). Analogically, the longer the Gra-
Table V. Quality of life assessment depending on educational background in the control group
Tabela V. Ocena jakości życia w zależności od wykształcenia w grupie kontrolnej
Parameter Elementary school High school University *p
Physical functioning 79.1 ± 21.0 85.1 ± 17.6 94.7 ± 9.24 0.0007
Role functioning — physical 70.8 ± 40.0 79.6 ± 33.2 82.5 ± 37.2 0.24
Bodily pain 52.0 ± 13.4 68.3 ± 25.6 80.3 ± 21.3 0.01
General heath 59.3 ± 12.5 69.5 ± 19.0 73.4 ± 15.4 0.12
Vitality 55.0 ± 17.8 61.4 ± 15.5 57.5 ± 10.4 0.33
Social functioning 77.0 ± 27.8 77.7 ± 19.4 75.6 ± 22.7 0.64
Role functioning — emotional 77.7 ± 40.3 80.2 ± 29.6 74.9 ± 33.9 0.69
Mental heath 58.6 ± 23.0 70.9 ± 15.2 72.8 ± 11.3 0.24
*Test for Spearman rank correlation coefficient
      Education
Table IV. Quality of life assessment depending on sex in the control group
Tabela IV. Ocena jakości życia w zależności od płci w grupie kontrolnej
p
Parameter Females Males  Mann-Whitney test
Physical functioning 88.3 ± 16.6 87.3 ± 14.5 0.57
Role functioning — physical 86.9 ± 27.1 52.3 ± 48.0 0.02
Bodily pain 72.6 ± 23.2 64.9 ± 28.3 0.38
General heath 70.6 ± 16.7 67.0 ± 20.0 0.64
Vitality 61.3 ± 12.8 51.4 ± 16.1 0.03
Social functioning 83.0 ± 15.5 53.4 ± 24.4 0.01
Role functioning — emotional 87.2 ± 24.3 42.4 ± 33.6 < 0.01
Mental heath 72.0 ± 14.3 63.6 ± 17.3 0.16
Gender
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ves’ disease lasted, the better the patients assessed their
mental health after the completed treatment (Rs = 0.41,
p < 0.05).
Discussion
Research conducted on GO patients indicate that their
quality of life worsens considerably. Even though oph-
thalmopathy is not recognized as a chronic disease, the
quality of life of people afflicted with this condition is
as bad as in the case of patients with chronic circulatory
and respiratory failure [11, 12].
What is more, the feeling of a decline in quality of
life may last for a relatively long time in GO patients.
Terwee et al. proved the unfavourable influence of
ophthalmopathy on quality of life even after a period
of more than 11 years from the end of therapy [13]. It
was also noticed that hyperthyroidism itself, without
coexisting eye changes, negatively affects quality of
life [7, 14].
In order to eliminate the adverse effects of hyperthy-
roidism on quality of life, patients in a state of euthyre-
osis and suffering from Graves’ disease for 37.4 months
on average were included in this study.
In the examined group of GO patients, quality of
life was significantly lower than in the control group,
which referred to all analysed spheres of life included
in the MOS SF-36 form. The differences were related to
patients’ opinions about their physical functioning,
physical and emotional role functioning, general health,
Figure 3. Comparison between quality of life in patients with Graves’ ophthalmopathy and healthy individuals
Rycina 3. Porównanie jakości życia u pacjentów z oftalmopatią tarczycową i osób zdrowych
Figure 4. Quality of life in patients with Graves’ ophthalmopathy before and after the therapy
Rycina 4. Jakość życia pacjentów z oftalmopatią tarczycową przed i po zastosowanym leczeniu
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vitality, social functioning, mental health, and bodily
pain. According to a Dutch study, the only quality of
life parameter which did not substantially differ in pa-
tients with ophthalmopathy compared to healthy indi-
viduals was bodily pain [5].
The relationship between sex and age of GO patients
and their quality of life assessment was not confirmed.
Other authors have reported that older patients perce-
ive their quality of life as lower, whereas young people
with GO are mainly upset by changes in their external
appearance [6, 13, 15].
In the case of healthy individuals, sex- and age-de-
pendent differences in quality of life assessment mo-
stly concerned vitality, physical and emotional role func-
tioning, social functioning, and general health.
Graves’ ophthalmopathy causes worsening of qu-
ality of life because it disturbs the widely understood
psychic and social sphere, and affects economic aspects
of patients’ and their families’ lives.
In the analysed group of GO patients, no correla-
tion was found between quality of life assessment and
duration time of Graves’ disease and ophthalmopathy.
By contrast, in the research by Kaahaly G et al., the du-
ration of the disease was longer, which was reflected in
a more negative assessment of quality of life [16]. Oph-
thalmopathy symptoms reduce the differences in qu-
ality of life assessment resulting from age, sex, and du-
ration of Graves’ disease and eye changes.
A higher level of education of ophthalmopathy pa-
tients combines with higher assessment of quality of life.
A similar correlation was observed by Terwee et al. [15].
Surprisingly, there is no correlation between quali-
ty of life assessed before the therapy, the disease activi-
ty (CAS), and the level of OI. One would expect that
patients with very advanced and/or active disease wo-
uld assess their quality of their life to be lower than tho-
se in whom pathological symptoms are less intensive.
Our results, however, coincide with the results obta-
ined by other authors who, using special questionna-
ires designed exclusively for GO patients, also did not
note any correlation between ophthalmopathy activity
or stage of development and quality of patients’ lives
[4, 5, 15].
The lack of such correlations probably proves that
quality of life deteriorates considerably in the initial
phase of the disease, before typical clinical symptoms
of the infiltrative form of ophthalmopathy appear.
In GO patients, positive changes in quality of life
were observed after oral treatment with steroids, orbi-
tal radiotherapy, and orbital decompression surgeries
[17, 18].
In our research, the mean OI and CAS values consi-
derably decreased after the six-week therapy. Additio-
nally, a positive correlation was proven between CAS
and OI. On the other hand, the patients perceived the
quality of their lives as significantly better only when
referring to physical role functioning, bodily pain, and
vitality. A direct correlation between OI, CAS, and qu-
ality of life was not observed either.
To our amazement, the good results of ophthalmo-
pathy treatment in the described group of patients was
not reflected in a substantially improved quality of life.
Perhaps the means of classification of the disease deve-
lopment and activity do not reveal the full range of the
problem associated with the evaluation of patients’ li-
ving comfort. On the other hand, one should remem-
ber the 6-week hospital stay of such patients, and the
high doses of glucocorticoids administered in cycles and
their influence on the central nervous system. Proba-
bly these factors also had an impact on the patients’
perception and caused them to find very little impro-
vement in their quality of life.
Conclusions
1. Graves’ ophthalmopathy causes a considerable wor-
sening of quality of life.
2. The stage of clinical development and activity of
ophthalmopathy are not reflected in quality of life.
3. Effectiveness of treatment for ophthalmopathy can-
not be evaluated based on changes in quality of pa-
tients’ lives.
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